

1 **Potency and Breadth of Neutralization after 3 doses of mRNA vaccines in**
2 **COVID-19 Convalescent and Naïve individuals**

3

4 Joanna Luczkowiak¹, Gonzalo Rivas², Nuria Labiod¹, Fátima Lasala¹, Marta
5 Rolo², Jaime Lora-Tamayo^{3,4}, Mikel Mancheno-Losa³, David Rial-Crestelo³,
6 Alfredo Pérez-Rivilla^{2,5}, María D. Folgueira^{1,2,5}, Rafael Delgado^{1,2,4,5}

7

8 1-Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain

9 2-Department of Microbiology. Hospital Universitario 12 de Octubre, Madrid,

10 Spain

11 3-Department of Internal Medicine. Hospital Universitario 12 de Octubre,

12 Madrid, Spain

13 4-CIBER de Enfermedades Infecciosas (CIBERINFEC - Instituto de Salud

14 Carlos III)

15 5-School of Medicine. Universidad Complutense. Madrid, Spain

16

17 *Corresponding author: Dr. Rafael Delgado, Servicio de Microbiología, Hospital

18 Universitario 12 de Octubre, Avenida de Córdoba sn, Madrid 28041 Spain,

19 Phone +34 669580985, e-mail: rafael.delgado@salud.madrid.org

20

21

22

23

24

25 **Abstract**

26 Third doses of mRNA COVID-19 vaccines induced a significant increase in
27 neutralizing potency and breadth in naïve individuals comparable with
28 convalescents who restored levels after the first two doses. These results
29 suggest a limit to elicit neutralization in the number of stimuli by infection or
30 vaccination with ancestral SARS-CoV-2 sequences

31 **Background**

32
33 The implementation of COVID-19 vaccines has been one of the main tools for
34 pandemic control. The contraction of humoral response after vaccination and
35 the emergence of the different SARS-COV-2 variants of concern (VoC), along
36 with a clear disproportion in the global availability of vaccines, have
37 represented an important challenge to achieve high levels of protection(1).
38 Vaccine coverage has been particularly challenged after the rapid spread of the
39 Omicron VoC which combines an unprecedented number of mutations in its
40 sequence clearly related with increased transmission efficiency and
41 neutralizing scape(2). After the first prime-boost administration of mRNA
42 vaccines, a third dose has shown an important boost of potency and breadth
43 of neutralizing response(3). Here we have investigated the neutralizing
44 response after the third mRNA vaccine dose against SARS-CoV-2 VoC and
45 SARS-CoV-1 in a cohort of COVID-19 convalescent patients in comparison
46 with only-vaccinated naïve individuals.

47 **Methods**

48
49 Participants: We have included 21 COVID-19 convalescent and 21 naïve
50 healthcare workers (HCW) from the Hospital Universitario 12 de Octubre in

51 Madrid, Spain. Both groups were part of a follow-up study (Solidarity II cohort,
52 IRB approval ref CEIm 20/157) and were recruited after informed consent and
53 randomly selected among those with serum samples available for the study
54 period. Mean age was 49 and 48 years for the convalescent and naïve groups,
55 respectively. All infections in convalescent individuals took place during the
56 epidemic wave of COVID-19 affecting Madrid during March-April 2020, and all
57 had a mild clinical evolution. All participants were vaccinated in January-
58 February 2021 with two doses of the Pfizer-BNT162b2 vaccine 21 days apart.
59 Blood samples were obtained at 61 days (range 42-77) and 242 days (range
60 238- 252) after the first dose in the COVID-19 convalescent group and at 67
61 days (range 49-97) and 241 (range 228-252) in the COVID-19 naïve group. A
62 third dose of 50 ug of the Moderna mRNA-1273 vaccine was administered in
63 December 2021 according with EMA recommendations(4). Participants with
64 documented SARS-CoV-2 infections by RT-PCR or serology (anti-N) were
65 excluded. From the original group, 15 samples from COVID-19 convalescent
66 and 12 from the naïve group were collected 48 days after the third dose (range
67 41-57).

68 Production of SARS-CoV-2 pseudotyped VSV: SARS-CoV-2 pseudotyped VSV
69 were produced according to a previously published protocol(5). The SARS-
70 CoV-2 Spike mutant D614G was generated by site-directed mutagenesis using
71 as an input DNA the expression vector encoding SARS-CoV-2 Spike_614D
72 protein (kindly provided by J. Garcia-Arriaza, CNB-CSIC). Spike sequences
73 from SARS-CoV-2 variant Alpha (B.1.1.7, GISAID: EPI_ISL_608430), SARS-
74 CoV-2 variant Beta (B.1.351, GISAID: EPI_ISL_712096), SARS-CoV-2 variant

75 Gamma (P.1, GISAID: EPI_ISL_833140), SARS-CoV-2 variant Delta (B.1.617.2,
76 GISAID: EPI_ISL_1970335) and SARS-CoV-2 variant Omicron (B.1.1.529,
77 GISAID: EPI_ISL_6640917) were synthesized and cloned into pcDNA3.1 by
78 GeneArt technology (Thermo Fisher Scientific GENEART GmbH, Regensburg,
79 Germany). SARS-CoV-1 Spike was purchased from SinoBiological, China (Cat.
80 No. VG40150-G-N).

81 Neutralization assay: The neutralization activity of sera was tested as described
82 previously(5). As a control, the neutralization assay included dilution series of
83 an external calibrant with assigned unitage of 813 International Units per ml
84 [IU/ml] for neutralization activity (WHO SARS-CoV-2 Serology International
85 Standard, 20/136, Frederick National Laboratory for Cancer Research)(6).
86 RBD-binding antibodies: Anti-RBD Ig titers were determined by an
87 electrochemiluminescence commercial assay (Elecsys Anti-SARS-CoV-2,
88 Roche Diagnostics, Basel, Switzerland) and were converted to WHO
89 International Standard Binding Antibody Units and expressed as BAU/mL
90 following the manufacturer instructions

91 **Results**

92
93 Results are described in Figure 1. In COVID-19 naïve individuals, neutralizing
94 titers after prime-boost vaccination with BNT-162b2 were very low against the
95 Omicron VoC (GMT 37 and 31 IU/mL at 2- and 8-months post vaccination
96 respectively) as compared with the group of COVID-19 convalescent
97 individuals (Geometric mean titer, GMT, 802 and 237 IU/mL) ($p < 0.001$).
98 However, the third dose of mRNA 1273 increased the levels of neutralization
99 against Omicron specially in the naïve group that achieved a high and

100 comparable neutralizing potency as the convalescent group (832 vs 894 IU/mL
101 respectively). Neutralizing levels for the same time points for SARS-CoV-2 VoC
102 Alpha, Beta, Gamma and Delta followed a similar pattern as Omicron,
103 significantly lower in naïve individuals after the first two doses ($p < 0.001$) and
104 comparable to convalescents after the third dose. This pattern of response had
105 a correlation with results obtained with RBD-binding total antibodies at the
106 same time points in both groups of participants (Figure 2). The neutralizing
107 titer against SARS-CoV-1 was as expected low for naïve individuals after the
108 first two doses and also increased significantly after the third dose (GMT 397
109 IU/mL) but this level was significantly lower than the achieved in the
110 convalescent group (GMT 768 IU/mL) ($p = 0.018$). (Figure 1).

111 **Discussion**

112
113 A third dose of an mRNA vaccine resulted as expected in an increase of the
114 neutralizing response whose potency and breadth were more significant in
115 naïve individuals as compared with COVID-19 convalescent patients. This later
116 group, as described(7), experienced a great neutralizing response with a wide
117 coverage against SARS-CoV-2 VoC including Omicron after the first two
118 doses. A third dose of an mRNA vaccine restored neutralizing levels in
119 convalescents after a waning process developed during the subsequent
120 months. The effect of a third dose in naïve individuals induced a significant
121 increase of neutralizing titers against the reference SARS-CoV-2 sequence that
122 exceeded the levels achieved after the first two doses (5-fold, $p < 0.0001$) and in
123 a similar range of titers achieved by convalescent (GMT 2469 and 3148 IU/mL
124 respectively). Neutralizing titers against VoC Alpha, Beta, Gamma and Delta

125 exhibited the same pattern of a significant increase in the naïve group as
126 compared with convalescent ($p < 0.001$). In a similar way, the neutralizing
127 activity against Omicron, from a very low titer with the first two doses after the
128 third dose was GMT 832 IU/ml, also in the same range as the level of
129 convalescents: GMT 894 IU/mL. These results support the fact that repeated
130 events of immune stimulation either by natural infection and/or vaccination are
131 required to achieved maximum levels of neutralizing response with a wide
132 breadth against SARS-CoV-2. The number of stimulation events is likely limited
133 to three, since a third dose of an mRNA vaccine did not significantly increase
134 the neutralizing levels achieved after two doses in COVID-19 convalescent
135 patients, as it has been recently observed(8). In the naïve group the third dose
136 of mRNA vaccine induced a clear boosting of neutralizing response in terms of
137 potency and breadth that reached that was comparable for the first time to the
138 levels of convalescents vaccinated. Affinity maturation of antibodies against
139 SARS-CoV-2 Spike protein induced by repeated exposures to infection by pre-
140 VoC SARS-CoV-2 and/or mRNA vaccines based in the ancestral sequence
141 appears to play a role in the increased breadth of neutralization demonstrated
142 in both groups against Omicron(9). However, maturation affinity of antibodies
143 after natural infection and vaccination, in the so-called hybrid immunity(10),
144 appears to be superior. This is highlighted by the fact the neutralizing levels
145 against the related but distant SARS-CoV-1 were significantly higher in the
146 convalescent group as compared with naïves (GMT 768 vs 397 IU/mL
147 respectively, $p = 0.018$). COVID-19 vaccines and specially those based in mRNA
148 confer durable protection against severe disease and death upon SARS-CoV-2

149 infection. This is most probably based in the stimulation of cell-mediated
150 immunity that seems to be well preserved against the circulating VoC(11).
151 However, at the upper respiratory tract mucosal level, neutralizing antibodies
152 are the main response that is able to block infection and the level of
153 neutralizing antibodies is considered the best correlate of protection for
154 COVID-19 vaccines(12). This response can be outsmarted by the great
155 capability of SARS-CoV-2 to accommodate changes in critical neutralizing
156 epitopes within the spike protein and particularly the RBD region. Three doses
157 of mRNA COVID-19 vaccines, being the third stimulus the most potent,
158 achieved high levels of neutralizing antibodies with a reasonable coverage of
159 VoC including the highly mutated Omicron. Based in the results obtained in
160 convalescent patients undergoing the same vaccination schedule it does not
161 appear that subsequent vaccine doses will achieve further potency. Affinity
162 maturation of antibodies after repeated stimuli, even induced by the ancestral
163 SARS-CoV-2 sequence, allows a wide coverage against VoC. This is especially
164 significant in convalescent-vaccinated that exhibit high levels of neutralization
165 against the related SARS-CoV-1. These results have implication in the
166 development of long-term vaccination strategies.
167


168 **Figure 1. Neutralizing activity against SARS-CoV-2 VoC and SARS-CoV-1**
169 **in vaccinated COVID-19 convalescent and naïve individuals**

170

171 COVID-19 convalescent vaccinated (n=21) individuals are presented as scatter
172 red dot plots and COVID-19 naïve vaccinated (n=21) are presented as scatter
173 blue dot plots. Both groups were tested at 2- and 8-months post two doses of
174 BNT162b2 vaccination (mpv) indicated on the graph as Vac2. Additionally,
175 15/21 of COVID-19 convalescent vaccinated and 12/21 of COVID-19 naïve
176 vaccinated were tested at 1.5 months post Moderna mRNA-1273 vaccination
177 indicated on the graph as Vac3. Neutralization potency of serum samples were
178 calibrated using WHO International Standard 20/136 and are presented on the
179 graph as International Units per ml [IU/ml]. Solid red lines and numbers
180 correspond to geometric mean in vaccinated COVID-19 convalescent
181 individuals. Solid blue lines and numbers correspond to geometric mean in
182 vaccinated COVID-19 naïve individuals. Dashed line marks the cut-off titer for
183 neutralization assay (45 IU/ml). NT50 was calculated from individual results
184 obtained by triplicates using a nonlinear regression model fit with settings for
185 log inhibitor versus normalized response curves by GraphPad Prism v8. ns: not
186 significant; *p<0.05; **p<0.01; ***p<0.001. Abbreviations: mpv, months
187 postvaccination; International Units per ml [IU/ml]; Vac2, 2 doses of BNT162b2
188 vaccination; Vac3, third dose of Moderna mRNA-1273 vaccination


189

190



192 **Figure 2. SARS-CoV-2 RBD-binding antibodies in vaccinated COVID-19**
193 **convalescent and naïve individuals**

194 COVID-19 convalescent vaccinated (n=21) individuals are presented as scatter
195 red dot plots and COVID-19 naïve vaccinated (n=21) are presented as scatter
196 blue dot plots. Both groups were tested at 2- and 8-months post two doses of
197 BNT162b2 vaccination (mpv) indicated on the graph as Vac2. Additionally,
198 15/21 of COVID-19 convalescent vaccinated and 12/21 of COVID-19 naïve
199 vaccinated were tested at 1.5 months post Moderna mRNA-1273 vaccination
200 indicated on the graph as Vac3. Solid red lines and numbers correspond to
201 geometric mean in vaccinated COVID-19 convalescent individuals. Solid blue
202 lines and numbers correspond to geometric mean in vaccinated COVID-19
203 naïve individuals. RBD-binding antibody titers are presented as BAU/ml. ns:
204 not significant; *p<0.05; **p<0.01; ***p<0.001. Abbreviations: mpv, months
205 postvaccination; IgG, immunoglobulin G; BAU/ml, binding antibody units per
206 ml; Vac2, 2 doses of BNT162b2 vaccination; Vac3, third dose of Moderna
207 mRNA-1273 vaccination
208



209
210

211 **Conflict of Interest Statement:**

212 All authors declare not having conflicts of interests related to this work

213

214 **Funding Statement:**

215 This work was supported by by grants from the Instituto de Investigación

216 Carlos III, ISCIII, (FIS PI1801007 and PI2100989), by the European Commission

217 Horizon 2020 Framework Programme: Project VIRUSCAN FETPROACT-2016:

218 731868, Horizon Europe Framework programme: Project EPIC-CROWN-2 ID:

219 101046084 and by Fundación Caixa-Health Research (Project StopEbola

220 HR18-00469) to RD. M.M-L holds a clinical research contract Río Hortega

221 (CM19/00226) from the Instituto de Salud Carlos III, ISCIII (Spanish Ministry of

222 Science, Innovation and Universities).

223

224 **Acknowledgments**

225 We are greatly thankful to all participants in the Solidarity II cohort study

226

227

228

229 **References**

230

231 1. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas
232 EJ, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. *New England*
233 *Journal of Medicine*. 2021;385:e85.

234 2. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et
235 al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *New England*
236 *Journal of Medicine*. 2021;386(6):599-601.

237 3. Wratil PR, Stern M, Priller A, Willmann A, Almanzar G, Vogel E, et al.
238 Three exposures to the spike protein of SARS-CoV-2 by either infection or
239 vaccination elicit superior neutralizing immunity to all variants of concern.
240 *Nature medicine*. 2022:DOI: 10.1038/s41591-022-01715-4.

241 4. Spikevax: EMA. EMA
242 recommendation on booster. Oct 25, 2021 2021 [Available from:
243 <https://www.ema.europa.eu/en/news/spikevax-ema-recommendation-booster>].

244 5. Luczkowiak J, Labiod N, Rivas G, Rolo M, Lasala F, Lora-Tamayo J, et
245 al. Neutralizing Response Against SARS-CoV-2 Variants 8 Months After
246 BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals. *The*
247 *Journal of Infectious Diseases*. 2021:DOI:10.1093/infdis/jiab634.

248 6. Zhu F, Althaus T, Tan CW, Costantini A, Chia WN, Van Vinh Chau N, et
249 al. WHO international standard for SARS-CoV-2 antibodies to determine
250 markers of protection. *Lancet Microbe*. 2022;3(2):e81-e2.

- 251 7. Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et
252 al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by
253 SARS-CoV-2 infection. *Science*. 2021:eabg9175.
- 254 8. Walls AC, Sprouse KR, Bowen JE, Joshi A, Franko N, Navarro MJ, et al.
255 SARS-CoV-2 breakthrough infections elicit potent, broad and durable
256 neutralizing antibody responses. *Cell*. 2022;185:872-80.
- 257 9. Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al.
258 Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a
259 Third mRNA Vaccine Dose. *bioRxiv*. 2022:2022.02.14.480394.
- 260 10. Crotty S. Hybrid immunity. *Science*. 2021;372(6549):1392.
- 261 11. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al.
262 T cell responses to SARS-CoV-2 spike cross-recognize Omicron. *Nature*. 2022.
- 263 12. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et
264 al. Neutralizing antibody levels are highly predictive of immune protection from
265 symptomatic SARS-CoV-2 infection. *Nature medicine*. 2021;27(7):1205-11.
- 266